Superbugs and Superdrugs (Nov 14 - 15, 2016)

Broadening horizons on the growing global threat of Antimicrobial resistance (AMR) for almost two decades at the sell-out Superbugs and Superdrugs conference in Europe, SMi is thrilled to announce the expansion of its antimicrobial portfolio of events across the Atlantic with the release of Superbugs and Superdrugs USA.

This year's show in Iselin, New Jersey, will play host to an audience of scientific leaders, funding bodies and drug discovery specialists, providing a focal point to discuss the latest clinical advancements and funding opportunities.

With huge interest from leaders in the field including pending confirmations from PAHO/WHO, Astra Zeneca and other senior industry representatives, we have worked closely with an expert panel of speakers to present an agenda that is shaping up to be the best Superbugs and Superdrugs event to date.

The programme will hone in on key topics such as public private partnerships, collaboration, RandD, scientific priorities for antibiotic discovery, novel antibacterial therapeutic approaches, antibiotic stewardship, rapid diagnostic tools, combination therapies, resistance prevention, plus much more!

Featured speakers include :
• Dr Christopher Houchens, Branch Chief, Antibacterial's Program, BARDA
• Dr Rosemarie Aurigemma, Chief, Biodefense Drug Development Section , NIH
• Dr Anthony Simon Lynch, Senior Scientific Director, Janssen Research and Development LLC
• Dr Annaliesa Anderson, Vice President and CSO Bacterial Vaccines, Pfizer
• Dr Alita Miller, Director of Biology, Entasis Therapeutics
• William J Weiss, Director, Pre-Clinical Services, UNT Health Science Center
• Dr Domingo Gargallo-Viola, Co-Founder and CSO, ABAC Therapeutics
• Dr David Cook, Chief Scientific Officer, Blueberry Therapeutics Ltd

Price :
Conference: USD 1899